- Home
- SNES vs PALI Comparison
SNES vs PALI Comparison
Compare SNES & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- PALI
- Stock Information
- Founded
- SNES 2004
- PALI 1996
- Country
- SNES United States
- PALI United States
- Employees
- SNES N/A
- PALI N/A
- Industry
- SNES Agricultural Chemicals
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNES Industrials
- PALI Health Care
- Exchange
- SNES Nasdaq
- PALI Nasdaq
- Market Cap
- SNES 2.9M
- PALI 3.2M
- IPO Year
- SNES 2016
- PALI N/A
- Fundamental
- Price
- SNES $1.95
- PALI $0.72
- Analyst Decision
- SNES Strong Buy
- PALI Strong Buy
- Analyst Count
- SNES 1
- PALI 2
- Target Price
- SNES $10.00
- PALI $23.00
- AVG Volume (30 Days)
- SNES 37.9K
- PALI 71.2K
- Earning Date
- SNES 05-08-2025
- PALI 05-12-2025
- Dividend Yield
- SNES N/A
- PALI N/A
- EPS Growth
- SNES N/A
- PALI N/A
- EPS
- SNES N/A
- PALI N/A
- Revenue
- SNES $1,857,000.00
- PALI N/A
- Revenue This Year
- SNES $130.53
- PALI N/A
- Revenue Next Year
- SNES $80.00
- PALI N/A
- P/E Ratio
- SNES N/A
- PALI N/A
- Revenue Growth
- SNES 55.66
- PALI N/A
- 52 Week Low
- SNES $1.30
- PALI $0.60
- 52 Week High
- SNES $9.80
- PALI $9.09
- Technical
- Relative Strength Index (RSI)
- SNES 49.49
- PALI 45.23
- Support Level
- SNES $1.30
- PALI $0.65
- Resistance Level
- SNES $1.75
- PALI $0.77
- Average True Range (ATR)
- SNES 0.20
- PALI 0.05
- MACD
- SNES 0.07
- PALI 0.02
- Stochastic Oscillator
- SNES 75.58
- PALI 70.59
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.